Dossier
Sue Ojageer
Coverage of Sue Ojageer in the Nexus archive.
- GLP-1 Microdosing: Risks, Benefits and What to Know Before Changing Your Dose
A growing trend of microdosing GLP-1 drugs like Ozempic and Wegovy is spreading via social media, with users altering doses to reduce costs and side effects. However, this practice lacks FDA approval and clinical testing, posing unpredictable health risks. Pharmacist Sue Ojageer warns that self-directed microdosing bypasses medical supervision and may not be safer than standard prescriptions.